Full Name
Professor Samra Turajlic
Job Title
Consultant Medical Oncologist
Company
Francis Crick Institute
Speaker Bio
Dr Samra Turajilc MA (OXON), MBBS, MRCP, PhD
Consultant Medical Oncologist, Skin and Renal Units
Royal Marsden NHS Foundation Trust
Group Leader, Cancer Dynamics Laboratory, The Francis Crick Institute
Biography
Samra Turajlic completed her undergraduate studies at Oxford University and her clinical training at UCL medical school, graduating in 2002. She completed general medical training in London teaching hospitals. She gained a PhD in 2013 from the Institute of Cancer Research in the field of melanoma. Dr Turajlic contributed the first insights into the genome landscape of non-UV associated melanomas, and genetic mechanisms of resistance to targeted therapies in melanoma. In 2014, she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute. Her post-doctoral work contributed the first evolutionary classification of renal cancer, and key evolutionary determinants of the disease course. In parallel, Dr Turajlic completed her training in medical oncology and in 2015 was appointed a Consultant Medical Oncologist on the Skin and Urology Units at the Royal Marsden NHS Foundation Trust focusing on the treatment of melanoma and renal cancer. In 2019 she was awarded an Advanced Clinician Scientist Fellowship from CRUK and became an independent Group Leader at the Francis Crick Institute. She divides her time between the clinic and her lab, Cancer Dynamics. Dr Turajlic is the Chief Investigator of translational studies aimed at developing and implementing an evolutionary understanding of cancer and treatment resistance for patient benefit. During the COVID-19 pandemic she led a large-scale effort to evaluate response to COVID vaccines in patients with cancer. Dr Turajlic has several roles in ESMO: Faculty member for Immunotherapy and Genitourinary cancers; Faculty coordinator for Translational research; Scientific Committee member for ESMO annual meeting, chairing the Translation Track in 2018-20; as well as ESMO IO meeting. Dr Turajlic leads the Melanoma GeCIP as part of Genomics England. She is a member of the NCRI Bladder and Renal Cancer Clinical Studies Group (UK), Uveal Melanoma Guidelines Group (UK), Coalition for a Cure, Kidney Cancer Association (US), WHO Classification of GU Cancers 2022 Editorial Board (Global); Scientific Advisory Board for Genomics England and Systems Biology Ireland. She is a section editor for eLIfe and IO Tech, and a member of the advisory board for Cell Reports Medicine.
Dr Turajlic is a Trustee of the Kidney Cancer Support Network and Melanoma Focus, patient advocacy groups. She is a Senior Editor at Macmillan Cancer Support. Dr Turajlic receives research funding from CRUK, Rosetrees Trust, the Royal Marsden Cancer Charity, the RMH/ICR Biomedical Research Centre, Melanoma Research Alliance, the National Institute for Health (US), and the US Department of Defence.
Consultant Medical Oncologist, Skin and Renal Units
Royal Marsden NHS Foundation Trust
Group Leader, Cancer Dynamics Laboratory, The Francis Crick Institute
Biography
Samra Turajlic completed her undergraduate studies at Oxford University and her clinical training at UCL medical school, graduating in 2002. She completed general medical training in London teaching hospitals. She gained a PhD in 2013 from the Institute of Cancer Research in the field of melanoma. Dr Turajlic contributed the first insights into the genome landscape of non-UV associated melanomas, and genetic mechanisms of resistance to targeted therapies in melanoma. In 2014, she was awarded a Cancer Research UK Clinician Scientist Fellowship to study cancer evolution at the Francis Crick Institute. Her post-doctoral work contributed the first evolutionary classification of renal cancer, and key evolutionary determinants of the disease course. In parallel, Dr Turajlic completed her training in medical oncology and in 2015 was appointed a Consultant Medical Oncologist on the Skin and Urology Units at the Royal Marsden NHS Foundation Trust focusing on the treatment of melanoma and renal cancer. In 2019 she was awarded an Advanced Clinician Scientist Fellowship from CRUK and became an independent Group Leader at the Francis Crick Institute. She divides her time between the clinic and her lab, Cancer Dynamics. Dr Turajlic is the Chief Investigator of translational studies aimed at developing and implementing an evolutionary understanding of cancer and treatment resistance for patient benefit. During the COVID-19 pandemic she led a large-scale effort to evaluate response to COVID vaccines in patients with cancer. Dr Turajlic has several roles in ESMO: Faculty member for Immunotherapy and Genitourinary cancers; Faculty coordinator for Translational research; Scientific Committee member for ESMO annual meeting, chairing the Translation Track in 2018-20; as well as ESMO IO meeting. Dr Turajlic leads the Melanoma GeCIP as part of Genomics England. She is a member of the NCRI Bladder and Renal Cancer Clinical Studies Group (UK), Uveal Melanoma Guidelines Group (UK), Coalition for a Cure, Kidney Cancer Association (US), WHO Classification of GU Cancers 2022 Editorial Board (Global); Scientific Advisory Board for Genomics England and Systems Biology Ireland. She is a section editor for eLIfe and IO Tech, and a member of the advisory board for Cell Reports Medicine.
Dr Turajlic is a Trustee of the Kidney Cancer Support Network and Melanoma Focus, patient advocacy groups. She is a Senior Editor at Macmillan Cancer Support. Dr Turajlic receives research funding from CRUK, Rosetrees Trust, the Royal Marsden Cancer Charity, the RMH/ICR Biomedical Research Centre, Melanoma Research Alliance, the National Institute for Health (US), and the US Department of Defence.
Speaking At
